# TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

> **NCT05427305** · PHASE3 · COMPLETED · sponsor: **BioDlink Biopharm Co., Ltd.** · enrollment: 549 (actual)

## Conditions studied

- Efficacy

## Interventions

- **DRUG:** TAB008
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05427305
- **Lead sponsor:** BioDlink Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2020-03-24
- **Final completion:** 2020-03-24
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05427305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05427305, "TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05427305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*